27134166|t|Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.
27134166|a|Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance. In one such mouse model, potent angiogenesis inhibitors elicit compartmental reorganization of cancer cells around remaining blood vessels. The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis. Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling. Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism. Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate. mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.
27134166	96	100	mTOR	GeneOrGeneProduct	56717
27134166	137	142	tumor	DiseaseOrPhenotypicFeature	D009369
27134166	161	165	VEGF	GeneOrGeneProduct	22339,7422
27134166	237	242	human	OrganismTaxon	9606
27134166	243	249	tumors	DiseaseOrPhenotypicFeature	D009369
27134166	254	259	mouse	OrganismTaxon	10090
27134166	270	276	cancer	DiseaseOrPhenotypicFeature	D009369
27134166	354	359	mouse	OrganismTaxon	10090
27134166	437	443	cancer	DiseaseOrPhenotypicFeature	D009369
27134166	519	524	GLUT1	GeneOrGeneProduct	20525
27134166	529	533	MCT4	GeneOrGeneProduct	80879
27134166	556	563	hypoxic	DiseaseOrPhenotypicFeature	D000860
27134166	575	580	HIF1a	GeneOrGeneProduct	15251
27134166	626	631	Tumor	DiseaseOrPhenotypicFeature	D009369
27134166	704	708	MCT1	GeneOrGeneProduct	20501
27134166	714	718	p-S6	GeneOrGeneProduct	72508
27134166	742	746	mTOR	GeneOrGeneProduct	56717
27134166	758	773	Normoxic cancer	DiseaseOrPhenotypicFeature	D009369
27134166	802	809	lactate	ChemicalEntity	D019344
27134166	840	844	mTOR	GeneOrGeneProduct	56717
27134166	859	868	glutamine	ChemicalEntity	D005973
27134166	892	899	lactate	ChemicalEntity	D019344
27134166	1009	1015	cancer	DiseaseOrPhenotypicFeature	D009369
27134166	1029	1036	glucose	ChemicalEntity	D005947
27134166	1048	1055	lactate	ChemicalEntity	D019344
27134166	1100	1107	lactate	ChemicalEntity	D019344
27134166	1109	1113	mTOR	GeneOrGeneProduct	56717
27134166	1226	1231	GLUT2	GeneOrGeneProduct	20526
27134166	Positive_Correlation	D005973	D019344	Novel
27134166	Positive_Correlation	D019344	56717	Novel
27134166	Negative_Correlation	56717	20526	Novel
27134166	Positive_Correlation	56717	D005973	Novel
27134166	Association	80879	15251	Novel
27134166	Association	20525	15251	Novel
27134166	Association	D009369	D005947	No
27134166	Association	D009369	D005973	Novel
27134166	Association	D009369	D019344	No
27134166	Positive_Correlation	D009369	56717	Novel
27134166	Association	D009369	72508	Novel
27134166	Association	D009369	20501	Novel
27134166	Association	D009369	7422	No
27134166	Association	D009369	22339	No